Back to news
BioCopy AG closes first tranche of Series A at CHF 9 million
Biel-Bienne, 7 May 2026 — BioCopy SA, a Swiss-German biopharmaceutical company headquartered in Basel, has announced the closing of the first CHF 9 million tranche of its Series A financing round. The proceeds will fund IND-enabling studies for the company's lead lung cancer candidate, which is now entering preclinical development. The first-in-human Phase 1 trial is targeted for the fourth quarter of 2027.
Haute Capital Partners SA contributed to this tranche on a dual basis: through a direct investment in BioCopy's share capital, and by bringing together several co-investors from its ecosystem around the project. This dual contribution reflects the active-investor approach HCP applies to its strategic holdings.
BioCopy is developing a new generation of TCR-mimetic (TCRm) bispecific antibodies, an emerging modality in immuno-oncology that targets intracellular tumor antigens previously inaccessible to conventional antibodies. The company's portfolio comprises five TCRm bispecific development candidates, derived from its proprietary ValidaTe platform. The lead candidate, now selected and fully optimized, demonstrates a superior safety and efficacy profile, supporting its progression into preclinical development.
The company, which operates an R&D facility in Emmendingen (Germany), also plans to expand its operational infrastructure across Switzerland, Germany and the United States. Subscription to the second CHF 6 million tranche is already underway.
About BioCopy SA
BioCopy SA is a Swiss-German biopharmaceutical company headquartered in Basel, with an R&D facility in Emmendingen (Germany). The company combines proprietary ultra-high-throughput screening technologies, artificial intelligence and wet-lab experimental feedback to develop next-generation biotherapeutics in immuno-oncology.
About Haute Capital Partners SA
Haute Capital Partners (BX Swiss: HAUTE) is Switzerland's listed private equity holding. Access high-growth Swiss companies through a single tradeable share, denominated in CHF. The company's registered shares are listed on the BX Swiss: Ticker: HAUTE | ISIN: CH1115678950 | Valor: 111567895 | www.haute.com
Investor Inquiries
Thibault Leroy Bürki
CEO | Haute Capital Partners SA | +41 32 321 35 35 | tb@haute.com
Media & General inquiries
Haute Capital Partners SA | +41 32 321 35 35 | info@haute.com
DISCLAIMER
This publication constitutes neither an offer to sell nor a solicitation to buy securities of the Company and it does not constitute a prospectus or a similar communication within the meaning of article 652a, 752 and/or 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the listing rules of the BX Swiss. The listing is being made solely by means of and based on the published securities prospectus (including any amendments thereto, if any). An investment decision regarding the securities of the Company should only be made based on the securities prospectus. The prospectus is available free of charge in Switzerland for 12 months following the first day of trading at HAUTE CAPITAL PARTNERS SA, Plänkestrasse 32, 2502 Biel/Bienne, Switzerland. This communication is being distributed only to, and is directed only at (i) persons outside the United Kingdom, (ii) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iii) high net worth entities, and other persons to whom it may otherwise lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as "Relevant Persons"). Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Any person who is not a Relevant Person must not act or rely on this communication or any of its contents. This communication does not constitute an "offer of securities to the public" within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation") of the securities referred to in it (the "Securities") in any member state of the European Economic Area (the "EEA"). The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States or to US persons (as such term is defined in Regulation S under the Securities Act) unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. The issuer of the securities has not registered, and does not intend to register, any portion of the securities in the United States, and does not intend to conduct a public offering of securities in the United States.